Home>Publications>Secukinumab provides greater 52-week sustained relief in dermatology-specific quality-of-life impact than ustekinumab
Gottlieb AB, Pariser D, Tsai TF, Pinter A, Zhou Y, Gilloteau I, Mordin M, Davenport E, Guana A, Reich K. Secukinumab provides greater 52-week sustained relief in dermatology-specific quality-of-life impact than ustekinumab. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Abstract not available at this time.
RTI Health Solutions®
The power of knowledge. The value of understanding.
Steeped in a tradition of rigor and process, we maintain a legacy of setting the scientific standards within our industry. We employ the right approaches and proven research practices to analyze evidence and draw meaningful insights. Our uncompromisingly ethical and objective researchers ensure that results will hold up to scrutiny and reveal the benefits, risks, value and potential of your products. Learn more.